1960s
Early attention
Accounts of ibogaine’s psychoactive effects and possible relevance to withdrawal or drug use began drawing attention outside its traditional ethnobotanical context.
Ibogaine & noribogaine
Research Tracker
A cautious, evergreen view of the research landscape around ibogaine treatment: what has been observed, what remains under study, where policy has shifted, and what the evidence does not yet establish.
Research activity, a completed study, or permission to study a compound does not equal treatment approval or clinical endorsement.
A bounded summary
What this tracker follows
Ibogaine is a naturally occurring psychoactive alkaloid associated with plants in the Apocynaceae family. Its history, pharmacology, and legal status are complex; the ibogaine overview is useful for basic orientation, while individual study reports are needed for specific claims.
This page tracks documented developments relevant to ibogaine and its metabolite noribogaine: historical milestones, observational findings, registered trials, regulatory actions, and recurring uncertainties. For a broader framing of the questions people bring to this subject, the Clear Almanac 62 overview places evidence and risk side by side rather than treating either as an afterthought.
Historical landmarks
A short timeline of an unsettled field
Interest in ibogaine as a possible intervention for substance-use problems has moved through informal use, case reports, observational work, and more recent regulated development. The sequence matters: later activity does not erase the limitations of earlier evidence.
1990s
Formal interest grows
Preclinical and early human research helped establish a scientific agenda, while safety concerns and regulatory barriers remained central.
2000s
Observational reports
Case series and follow-up reports described changes in substance use for some participants, but generally lacked the controls needed to establish causation.
Today
Targeted development
Ibogaine and noribogaine continue to appear in registries and development discussions, with study protocols, endpoints, and safety monitoring determining what can be concluded.
Findings & trial status
What studies can—and cannot—show
Several observational studies have reported reductions in substance use or withdrawal-related symptoms after ibogaine exposure. Those reports can be important signals, especially when outcomes are followed over time. They are not, however, equivalent to blinded or randomized comparisons, and participant selection, concurrent support, self-reporting, and loss to follow-up can all shape the result.
Trial registries are a practical way to distinguish a completed, recruiting, active, or planned protocol from promotional language. The registered ibogaine studies search at ClinicalTrials.gov provides a current starting point for verifying study records and their listed statuses.
Observational findings
Potentially informative, but vulnerable to confounding and usually insufficient to establish an intervention’s effectiveness or safety profile.
Controlled trials
A controlled trial may address a narrower question under defined conditions. A protocol’s presence or completion does not itself settle the result.
Noribogaine research
Noribogaine is studied separately from ibogaine, including in regulated development settings; findings for one compound should not automatically be transferred to the other.
Policy & development
Regulatory movement needs careful reading
Ibogaine remains tightly controlled in the United States
The U.S. Drug Enforcement Administration lists ibogaine as a Schedule I controlled substance. The agency’s controlled-substance scheduling information explains the federal scheduling framework, which is distinct from any state, international, or research-specific context.
Investigational work has a defined pathway
In the United States, studies involving investigational drugs generally operate through FDA-regulated pathways, including investigational new drug processes. The FDA’s IND application guidance describes the purpose of that route; it should not be read as proof that a compound is approved or established.
Noribogaine has drawn separate development interest
References to FDA allowance of noribogaine studies indicate an authorization to investigate under a particular development program, not a conclusion about clinical effectiveness. The status of any individual program should be checked against a primary registry entry, sponsor disclosure, or regulator document.
Policy and evidence do not move at the same speed
Changes in research permissions, state-level discussion, or public interest may increase activity before high-quality evidence answers the questions that matter most for real-world decision-making.
Evidence gaps
Questions the record still leaves open
Understanding how to weigh a study is part of risk clarity. The practical approach described in our evidence-navigation approach is to separate a documented finding from the larger claims people may build around it.
Does research establish ibogaine as an approved treatment?
No. Observational reports and early clinical work can generate hypotheses, but they do not establish approval, a standard dose, or broad clinical endorsement. The safety considerations page explains why study findings cannot be separated from known and potential risks.
What is the role of noribogaine in the research landscape?
Noribogaine is an active metabolite of ibogaine that is being studied separately in regulated development programs. Study authorization is not the same as a finding of safety, effectiveness, or approval, and compound-specific evidence should remain compound-specific.
What evidence gaps still matter most?
Important gaps include controlled comparisons, dosing, cardiac and other safety risks, interaction risks, selection of participants, and long-term outcomes. For background on why trial design affects interpretation, the randomized controlled trial framework offers a concise description of the comparison method often used to reduce bias.
Use the record carefully
Keep the question proportional to the evidence.
Primary reports, trial records, and regulator materials can clarify what was actually studied and what was not. Where the record is preliminary, the most accurate conclusion may simply be that more evidence is needed.